Showing results (121-130 of 142) with videos related to

Sort By:
Pageof 15
The Lancet. Oncology|September 7, 2012
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trialTakayuki Yoshino, Nobuyuki Mizunuma, Kentaro Yamazaki, et al.
BMJ Open|September 1, 2018
Early prediction of lenvatinib treatment efficacy by using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observational studySatoshi Takeuchi, Tohru Shiga, Kenji Hirata, et al.
BMC Cancer|October 30, 2021
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancerShun Yamamoto, Kengo Nagashima, Takeshi Kawakami, et al.
EJNMMI Research|July 17, 2023
Early prediction of treatment outcome for lenvatinib using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised studySatoshi Takeuchi, Kenji Hirata, Keiichi Magota, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 27, 2016
[A Case of Delayed Vascular Injury as a Complication Related to Implanted Central Venous Port Catheter]Tetsuya Sumiyoshi, Tomohiro Kondo, Ryoji Fujii, et al.
Cancer Chemotherapy and Pharmacology|September 23, 2020
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathyMasahito Kotaka, Yoji Saito, Takeshi Kato, et al.
Cancer Science|August 24, 2018
Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II studyHiroyuki Ohnuma, Yasushi Sato, Naotaka Hayasaka, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|December 2, 2021
Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study GroupSohei Satoi, Naminatsu Takahara, Tsutomu Fujii, et al.
The Oncologist|May 17, 2022
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603Yasuyuki Kawamoto, Satoshi Yuki, Kentaro Sawada, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2017
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancerEric Van Cutsem, Robert J Mayer, Stéphanie Laurent, et al.
Pageof 15